Men's Health News

RSS

Highlights from Mayo Clinic's Discovery's Edge research magazine

Here are highlights from the winter issue of Discovery's Edge, Mayo Clinic's research magazine.

24 Dec 2009

Study suggests routine evaluation does not predict prostate cancer

On the heels of the American Cancer Society's recent controversial response to breast and prostate cancer screenings guidelines, a new study from the Mayo Clinic has emerged analyzing the correlation between prostate-specific antigen (PSA) levels and prostate size. The study discovered that routine annual evaluation of prostate growth does not predict the development of prostate cancer.

24 Dec 2009

Interdisciplinary approach essential for treating men’s' sexual dysfunction

Modern, couple-oriented treatment for male sexual dysfunction takes the psychosocial aspects of sex into account, as well as focussing on the purely physical aspects of the problem.

24 Dec 2009

Relatives of men with cryptorchidism or hypospadias not at risk of developing testicular germ cell cancer

Boys with the sexual birth defects known as hypospadias and cryptorchidism are at risk for developing testicular germ cell cancer, but their relatives are not, according to a new study published online December 21 in the Journal of the National Cancer Institute.

22 Dec 2009

Teva Pharmaceutical Industries, OncoGenex Pharmaceuticals announce collaboration in cancer therapy

Teva Pharmaceutical Industries Ltd. and OncoGenex Pharmaceuticals, Inc. announced today that they have entered into a global license and collaboration agreement to develop and commercialize OGX-011, as well as an agreement to purchase shares in OncoGenex. OGX-011 is a Phase III cancer therapy designed to inhibit cancer treatment resistance.

21 Dec 2009

VA apologizes for faulty prostate-cancer program in Pa. but denies radiation violations

"The Department of Veterans Affairs yesterday apologized repeatedly for a prostate-cancer program that gave incorrect radiation doses to veterans for six years at its main Philadelphia hospital," The Philadelphia Inquirer reports.

18 Dec 2009

European CHMP announces positive opinion for Amgen's Prolia marketing authorization

Amgen Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has announced a positive opinion for the marketing authorization of Prolia((TM)) (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures.

18 Dec 2009

Advanced Medical Diagnostics SA to open 15 Tissue Differentiation Diagnostic Centres

Advanced Medical Diagnostics SA, a privately held company committed to providing innovative computer-aided solutions (HistoScanning™) that improve the diagnostic interpretation of ultrasound scans, today announced a collaboration with the BUND-DER-UROLOGEN for the opening of 15 Tissue Differentiation Diagnostic Centres.

18 Dec 2009

Link between ill-health and retirement age varies across European countries

A study of the impact of health "shocks" on the decision of individuals to retire early found that for men, rapidly deteriorating health had the largest impact in Ireland, Portugal, Greece and Spain.

18 Dec 2009

Shift working may accelerate metabolic syndrome

Shift work exposures can accelerate metabolic syndrome (MetS) development among the large population of middle-aged males with elevated alanine aminotransferase (ALT). Elevated serum alanine aminotransferase (e-ALT) is a common abnormality of health examinations in middle-aged working populations.

17 Dec 2009

New offers on penis extender device during holiday season

Just in time for the holidays, Quick Extender Pro™, an industry leader in penis enlargement, is offering 25% off their penis extender device along with a free bonus holiday gift.

17 Dec 2009

Top-line efficacy and safety results from Phase 2b clinical trial of XIAFLEX announced

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced top-line efficacy and safety results from a Phase 2b clinical trial of XIAFLEX(TM) for the treatment of Peyronie's disease.

17 Dec 2009

Makefield Therapeutics to patent applications covering its Hybrid Nanoparticle drug delivery platform

Makefield Therapeutics, Inc., an emerging therapeutics company, today announced that it has obtained an exclusive license from Albert Einstein College of Medicine of Yeshiva University to patent applications covering Makefield's biodegradable Hybrid Nanoparticles™, a versatile new drug delivery platform.

16 Dec 2009

Positive results from Auxilium Pharmaceuticals' XIAFLEX Peyronie's disease phase IIb trial

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced top-line efficacy and safety results for the phase IIb clinical trial for XIAFLEX™ (collagenase clostridium histolyticum) in the treatment of Peyronie's disease.

16 Dec 2009

Prostate cancer tests promised but not delivered

Men's Health Network calls on Congress to ensure that healthcare reform does not override the prostate cancer testing benefit currently required of insurance companies in 37 states.

16 Dec 2009

Teens, contraception and unplanned pregnancy

Nearly all unmarried young adults ages 18-29 believe pregnancy is something that should be planned (94% of men and 86% of women) and say that it is important to avoid pregnancy in their lives right now (86% of men and 88% of women), according to new research released by The National Campaign to Prevent Teen and Unplanned Pregnancy.

15 Dec 2009

Preventing tumours from making new blood vessels can also prevent spread of cancer

Patients with advanced prostate cancer are often treated with hormones, but when the tumours start growing again they have more and different blood vessels, reveals a thesis from the Sahlgrenska Academy, at the University of Gothenburg, Sweden. This discovery paves the way for new treatments for hormone-resistant prostate cancer.

15 Dec 2009

Pure populations of immature cells that enable male reproduction isolated and transplanted

Reproductive researchers from the University of Pennsylvania and The Children's Hospital of Philadelphia have succeeded in isolating and transplanting pure populations of the immature cells that enable male reproduction in two species-human spermatogonia and mouse gonocytes. These germline stem cells, taken from testis biopsies, demonstrated viability following transplantation to mouse testes within a controlled laboratory setting.

15 Dec 2009

Increased physical activity decreases risk of colorectal cancer

Increased physical activity appears to be associated with a lower risk of cancer-specific and overall death in men with a history of colorectal cancer that has not spread to other parts of the body, according to a report in the December 14/28 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

15 Dec 2009

New program to help maintain bone health in men with prostate cancer on ADT announced

Watson Pharmaceuticals, Inc. today announced a new program encouraging health professionals to help maintain the bone health of prostate cancer patients who are on long-term androgen deprivation therapy (ADT).

15 Dec 2009

Men's Health News

Highlights from Mayo Clinic's Discovery's Edge research magazine

Study suggests routine evaluation does not predict prostate cancer

Interdisciplinary approach essential for treating men’s' sexual dysfunction

Relatives of men with cryptorchidism or hypospadias not at risk of developing testicular germ cell cancer

Teva Pharmaceutical Industries, OncoGenex Pharmaceuticals announce collaboration in cancer therapy

VA apologizes for faulty prostate-cancer program in Pa. but denies radiation violations

European CHMP announces positive opinion for Amgen's Prolia marketing authorization

Advanced Medical Diagnostics SA to open 15 Tissue Differentiation Diagnostic Centres

Link between ill-health and retirement age varies across European countries

Shift working may accelerate metabolic syndrome

New offers on penis extender device during holiday season

Top-line efficacy and safety results from Phase 2b clinical trial of XIAFLEX announced

Makefield Therapeutics to patent applications covering its Hybrid Nanoparticle drug delivery platform

Positive results from Auxilium Pharmaceuticals' XIAFLEX Peyronie's disease phase IIb trial

Prostate cancer tests promised but not delivered

Teens, contraception and unplanned pregnancy

Preventing tumours from making new blood vessels can also prevent spread of cancer

Pure populations of immature cells that enable male reproduction isolated and transplanted

Increased physical activity decreases risk of colorectal cancer

New program to help maintain bone health in men with prostate cancer on ADT announced

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News